Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Judith Raimbourg's publication output changed over time?
ScholarIQpublication output · 2017–2025
Output declined50% over the shown period — from 2 works in 2017 to 1 in 2025.
2
1
2
2
1
1
1
1
20172018201920202021202320242025
What are the most-cited papers on Judith Raimbourg?
ScholarIQmost cited works
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
Manish A. Shah, Takashi Kojima, Daniel Hochhauser, Peter C. Enzinger, Judith Raimbourg, Antoine Hollebecque, Florian Lordick, Sung‐Bae Kim, Masahiro Tajika, Heung Tae Kim, A. Craig Lockhart, Hendrik-Tobias Arkenau, Farid El-Hajbi, Mukul Gupta, Per Pfeiffer, Qi Liu, Jared Lunceford, Soonmo Peter Kang, Pooja Bhagia, Ken Kato
JAMA Oncology. 2018523 CitationsOPEN ACCESS
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Myriam Delaunay, J. Cadranel, Amélie Lusque, Nicolás Meyer, V. Gounant, Denis Moro‐Sibilot, Jean‐Marie Michot, Judith Raimbourg, Nicolas Girard, Florian Guisier, David Planchard, Anne-Cécile Métivier, Pascale Tomasini, Éric Dansin, M. Pérol, M. Campana, Oliver Gautschi, Martin Früh, Jean-David Fumet, Clarisse Audigier-Valette, S. Couraud, Stéphane Dalle, M.‐T. Leccia, M. Jaffro, S. Collot, Grégoire Prévôt, Julie Milia, Julien Mazières
S4210207896. 2017424 CitationsOPEN ACCESS
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Płużański, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Żurawski, Aurelia Alexandru, A. Vergnenègre, Judith Raimbourg, Kynan Feeney, Sang‐We Kim, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck
Journal of Thoracic Oncology. 2021324 CitationsOPEN ACCESS
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O’Neil, John M. Wallmark, David Lorente, Elena Élez, Judith Raimbourg, Carlos Gomez‐Roca, Samuel Ejadi, Sarina A. Piha‐Paul, Mark N. Stein, Albiruni R. Abdul Razak, Katia Dotti, Armando Santoro, Roger B. Cohen, M. Gould, Sanatan Saraf, Karen Stein, Sae‐Won Han
PLoS ONE. 2017306 CitationsOPEN ACCESS
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Martin Reck, Michael Schenker, Ki Hyeong Lee, Mariano Provencio, Makoto Nishio, Krzysztof Leśniewski-Kmak, Randeep Sangha, Samreen Ahmed, Judith Raimbourg, Kynan Feeney, R. Corre, Fábio Franke, Eduardo Richardet, John R. Penrod, Yong Yuan, Faith E. Nathan, Prabhu Bhagavatheeswaran, Michael DeRosa, Fiona Taylor, Rachael Lawrance, Julie R. Brahmer
European Journal of Cancer. 2019218 CitationsOPEN ACCESS
Related on ScholarIQ
Institut de Cancérologie de l'Ouest
Institution
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
Paper
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Paper
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Paper
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Paper
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Paper